Your browser doesn't support javascript.
loading
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS).
Wen, Ming-Tao; Luo, Di; Li, Jia-Cheng; Lu, Bo-Wen; Ling, Pei-Xue; Liu, Fei; Li, Gang.
Afiliación
  • Wen MT; The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Luo D; Orthopaedic, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Li JC; The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Lu BW; Orthopaedic, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Ling PX; The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Liu F; Shandong Academy of Pharmaceutical Science, Key Laboratory of Biopharmaceuticals, Jinan, China.
  • Li G; The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China.
Expert Opin Drug Saf ; : 1-10, 2024 Jul 18.
Article en En | MEDLINE | ID: mdl-39016171
ABSTRACT

BACKGROUND:

Osteoporosis (OP), characterized by low bone mass and increased fracture risk, is a prevalent skeletal disorder. Teriparatide (TP) and abaloparatide (ABL) are anabolic agents that may reduce fracture incidence, but their impact on musculoskeletal and connective tissue disorders (MCTD) risk is uncertain. RESEARCH DESIGN AND

METHODS:

A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug. Multiple data mining algorithms, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS), were employed to detect MCTD safety signals.

RESULTS:

A total of 366,747 TP-related and 422,377 ABL-related cases were identified, predominantly among female patients aged ≥45 years. The top specific AEs involved musculoskeletal, connective tissue, and administration site disorders. Comparative analysis revealed a higher frequency of AEs related to the nervous, cardiovascular, and gastrointestinal systems for ABL compared to TP. Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.

CONCLUSION:

The analysis suggests a potential MCTD risk with TP and ABL treatment in OP patients, highlighting the need for AE monitoring and management in clinical practice. This contributes to a better understanding of the safety profiles of these anabolic medications.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido